Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13817MR)

This product GTTS-WQ13817MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13817MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15454MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ308MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ11000MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ1897MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ5018MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ6291MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ1159MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ12183MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MORAb-022
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW